HK1130478A1 - Chemical in situ sulphonating process - Google Patents

Chemical in situ sulphonating process

Info

Publication number
HK1130478A1
HK1130478A1 HK09108619.5A HK09108619A HK1130478A1 HK 1130478 A1 HK1130478 A1 HK 1130478A1 HK 09108619 A HK09108619 A HK 09108619A HK 1130478 A1 HK1130478 A1 HK 1130478A1
Authority
HK
Hong Kong
Prior art keywords
sulphonating
situ
chemical
sulphonating process
situ sulphonating
Prior art date
Application number
HK09108619.5A
Other languages
English (en)
Inventor
Joergen Blixt
Michael D Golden
Philip John Hogan
David Michael Glanville Martin
Francis Joseph Montgomery
Zakariya Patel
John David Pittam
George Joseph Sependa
Christopher John Squire
Nicholas Cartwright Alexander Wright
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35395001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1130478(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1130478A1 publication Critical patent/HK1130478A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK09108619.5A 2005-09-30 2009-09-21 Chemical in situ sulphonating process HK1130478A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0519879.1A GB0519879D0 (en) 2005-09-30 2005-09-30 Chemical process

Publications (1)

Publication Number Publication Date
HK1130478A1 true HK1130478A1 (en) 2009-12-31

Family

ID=35395001

Family Applications (2)

Application Number Title Priority Date Filing Date
HK08113582.9A HK1122553A1 (en) 2005-09-30 2008-12-15 Chemical process
HK09108619.5A HK1130478A1 (en) 2005-09-30 2009-09-21 Chemical in situ sulphonating process

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK08113582.9A HK1122553A1 (en) 2005-09-30 2008-12-15 Chemical process

Country Status (32)

Country Link
US (8) US8163926B2 (xx)
EP (2) EP2053048B8 (xx)
JP (2) JP5213715B2 (xx)
KR (1) KR101307641B1 (xx)
CN (3) CN102503898B (xx)
AR (1) AR055671A1 (xx)
AT (2) ATE448218T1 (xx)
AU (1) AU2006296367B2 (xx)
BR (1) BRPI0616715A2 (xx)
CA (2) CA2745829C (xx)
CY (2) CY1110275T1 (xx)
DE (2) DE602006017004D1 (xx)
DK (2) DK2053048T3 (xx)
ES (2) ES2350513T3 (xx)
GB (1) GB0519879D0 (xx)
HK (2) HK1122553A1 (xx)
HR (2) HRP20100019T1 (xx)
IL (2) IL190172A (xx)
ME (2) ME01531B (xx)
MY (2) MY149834A (xx)
NO (1) NO342152B1 (xx)
NZ (2) NZ566566A (xx)
PL (2) PL2053048T3 (xx)
PT (2) PT2053048E (xx)
RS (2) RS51515B (xx)
RU (1) RU2448102C2 (xx)
SG (1) SG165416A1 (xx)
SI (2) SI1943240T1 (xx)
TW (2) TWI424991B (xx)
UY (1) UY29824A1 (xx)
WO (1) WO2007036713A2 (xx)
ZA (1) ZA200802416B (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1474420E (pt) * 2002-02-01 2012-05-10 Astrazeneca Ab Compostos de quinazolina
GB0519879D0 (en) * 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
CL2007003158A1 (es) * 2006-11-02 2008-05-16 Astrazeneca Ab Procedimiento de preparacion de compuestos derivados de quinazolina o sus sales farmaceuticamente aceptables; compuestos intermediarios; procedimiento de preparacion.
ES2547902T3 (es) * 2011-09-01 2015-10-09 Symrise Ag Procedimiento para la preparación de derivados de indanona
KR20150043465A (ko) * 2012-08-15 2015-04-22 글락소 그룹 리미티드 화학 공정
CN104098544A (zh) * 2013-04-07 2014-10-15 浙江九洲药物科技有限公司 一种凡德他尼的制备方法
CN106397401B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种抗癌药物的晶体化合物及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870083A (en) * 1987-11-24 1989-09-26 Merrell Dow Pharmaceuticals Inc. 1,4-Disubstituted-piperidinyl compounds useful as analgesics and muscle relaxants
JP2829744B2 (ja) 1989-05-31 1998-12-02 川研ファインケミカル株式会社 ピペリジンカルボン酸類の製造方法
AU8506791A (en) 1990-10-01 1992-04-28 Janssen Pharmaceutica N.V. Novel 4-piperidinylcarbonyl derivatives
JP2659107B2 (ja) 1991-03-28 1997-09-30 エーザイ株式会社 複素環式―環式アミン誘導体
DE69222637T2 (de) 1991-05-10 1998-02-26 Rhone Poulenc Rorer Int Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5624926A (en) 1993-02-18 1997-04-29 Kyowa Hakko Kogyo Co., Ltd. Piperidinyl-dioxoquinazolines as adenosine reuptake inhibitors
CN1058262C (zh) * 1993-05-26 2000-11-08 森德克斯(美国)股份有限公司 新颖的1－苯基烷酮5－ht4受体配位体
DE4326344A1 (de) 1993-08-05 1995-02-09 Thomae Gmbh Dr K Carbonamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE69504300T2 (de) * 1994-01-13 1999-04-29 Merck Sharp & Dohme Ltd., Hoddesdon, Hertfordshire Gem-bissubstituierte azazyclische tachykinin-antagonisten
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DK0885198T3 (da) 1996-03-05 2002-03-25 Astrazeneca Ab 4-Anilinoquinazolinderivater
WO1998010767A2 (en) 1996-09-13 1998-03-19 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
NZ518028A (en) * 1999-11-05 2004-03-26 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
GB0126879D0 (en) 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
WO2003053361A2 (en) 2001-12-20 2003-07-03 Osi Pharmaceuticals, Inc. PYRROLOPYRIMIDINE A2b SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE
PT1474420E (pt) 2002-02-01 2012-05-10 Astrazeneca Ab Compostos de quinazolina
JP4389205B2 (ja) 2002-02-06 2009-12-24 宇部興産株式会社 ４−アミノキナゾリン化合物の製法
AU2003249000B2 (en) 2002-08-09 2007-04-05 Astrazeneca Ab Combination of ZD6474, an inhibitor of the vasuclar endothelial growth factor receptor, with radiotherapy in the treatment of cancer
GB0218526D0 (en) 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
WO2004071397A2 (en) 2003-02-13 2004-08-26 Astrazeneca Ab Combination therapy of zd6474 with 5-fu or/and cpt-11
NZ544458A (en) 2003-07-10 2009-04-30 Astrazeneca Ab Use of the quinazoline derivative ZD6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
GB0318423D0 (en) 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
GB0519879D0 (en) * 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process

Also Published As

Publication number Publication date
AR055671A1 (es) 2007-08-29
PL1943240T3 (pl) 2010-04-30
NZ593930A (en) 2013-02-22
US20190263782A1 (en) 2019-08-29
US9815816B2 (en) 2017-11-14
TW200745036A (en) 2007-12-16
EP2053048B8 (en) 2011-09-21
ME01466B (me) 2014-04-20
ZA200802416B (en) 2009-01-28
US8865899B2 (en) 2014-10-21
EP1943240A2 (en) 2008-07-16
CY1110887T1 (el) 2015-06-10
ES2350513T3 (es) 2011-01-24
JP2013063998A (ja) 2013-04-11
IL190172A0 (en) 2008-08-07
CA2624045A1 (en) 2007-04-05
JP5654546B2 (ja) 2015-01-14
DK2053048T3 (da) 2010-11-29
AU2006296367A1 (en) 2007-04-05
KR101307641B1 (ko) 2013-09-12
ATE481399T1 (de) 2010-10-15
EP1943240B1 (en) 2009-11-11
US20090203905A1 (en) 2009-08-13
US20140378684A1 (en) 2014-12-25
CN102503898A (zh) 2012-06-20
GB0519879D0 (en) 2005-11-09
CN102503933B (zh) 2014-06-25
US20120095229A1 (en) 2012-04-19
RU2448102C2 (ru) 2012-04-20
CN101277948B (zh) 2013-03-13
AU2006296367B2 (en) 2011-08-11
WO2007036713A3 (en) 2007-06-14
CA2745829A1 (en) 2007-04-05
NO20081267L (no) 2008-04-30
CY1110275T1 (el) 2015-01-14
JP2009510039A (ja) 2009-03-12
MY149834A (en) 2013-10-31
ME01531B (me) 2014-04-20
US10344015B2 (en) 2019-07-09
DK1943240T3 (da) 2010-03-01
EP2053048B1 (en) 2010-09-15
JP5213715B2 (ja) 2013-06-19
CN102503898B (zh) 2015-03-25
WO2007036713A2 (en) 2007-04-05
HK1122553A1 (en) 2009-05-22
NZ566566A (en) 2011-08-26
BRPI0616715A2 (pt) 2011-06-28
EP2053048A1 (en) 2009-04-29
CN101277948A (zh) 2008-10-01
US20160185754A1 (en) 2016-06-30
UY29824A1 (es) 2007-04-30
IL190172A (en) 2014-05-28
KR20080049114A (ko) 2008-06-03
SG165416A1 (en) 2010-10-28
TW201018660A (en) 2010-05-16
PT2053048E (pt) 2010-11-10
SI2053048T1 (sl) 2010-12-31
RS51515B (en) 2011-06-30
MY145540A (en) 2012-02-29
HRP20100620T1 (hr) 2010-12-31
DE602006017004D1 (de) 2010-10-28
HRP20100019T1 (hr) 2010-02-28
SI1943240T1 (sl) 2010-02-26
US20220033377A1 (en) 2022-02-03
ES2335435T3 (es) 2010-03-26
RS51263B (sr) 2010-12-31
CA2624045C (en) 2012-05-22
CN102503933A (zh) 2012-06-20
US8163926B2 (en) 2012-04-24
US20180118716A1 (en) 2018-05-03
TWI424991B (zh) 2014-02-01
NO342152B1 (no) 2018-04-03
ATE448218T1 (de) 2009-11-15
US20240150317A1 (en) 2024-05-09
PT1943240E (pt) 2010-01-11
CA2745829C (en) 2013-07-02
TWI328580B (en) 2010-08-11
RU2008116573A (ru) 2009-11-10
IL227574A (en) 2015-08-31
PL2053048T3 (pl) 2011-03-31
DE602006010428D1 (de) 2009-12-24

Similar Documents

Publication Publication Date Title
GB0514078D0 (en) Chemical process
IL208667A0 (en) Chemical process
GB0428328D0 (en) Chemical process
HK1130478A1 (en) Chemical in situ sulphonating process
TWI366562B (en) Chemical process
GB0426057D0 (en) Chemical process
GB0522061D0 (en) Chemical process
GB0501102D0 (en) Process
GB0403744D0 (en) Chemical process
GB0427697D0 (en) Chemical process
GB0426059D0 (en) Chemical process
EP1915131A4 (en) PROCESS
GB0515926D0 (en) Chemical process
GB0411596D0 (en) Chemical process
GB0517051D0 (en) Chemical process
GB0501100D0 (en) Process
GB0428103D0 (en) Chemical Process
GB0508515D0 (en) Chemical process
GB0514137D0 (en) Chemical process
GB0512049D0 (en) Chemical process
GB0514086D0 (en) Chemical process
GB0502963D0 (en) Chemical process
GB0508808D0 (en) Chemical process
GB0517413D0 (en) Chemical process
GB0522431D0 (en) Chemical process

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190927